mAbxience

Company snapshot

mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in dev

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for mAbxience. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for mAbxience.

1. Jun 8, 2026 Clinical update

   MB04-A-01-23 — Phase 1

2. Jun 8, 2026 Clinical update

   MB12-C-02-24 — Phase 3

3. Jun 8, 2026 Clinical update

   MB11-C-01-25 — Phase 3

4. Jun 8, 2026 Clinical update

   MB04-C-01-23 — Phase 3

5. May 26, 2026 Clinical update

   MB02-SP — Phase 1

View all clinical trial activity →

• What is mAbxience?

  Mabxience Research SL is a pharma organization headquartered in Madrid, ES. Primary therapeutic focus areas include Not applicable, Healthy Volunteers, advanced/metastatic non-squamous non-small cell lung cancer (NSCLC), Rheumatoid Arthritis, Previously Untreated Advanced (Unrese

• Is mAbxience publicly traded?

  mAbxience appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does mAbxience develop or market?

  We link 10 drug profile(s) where mAbxience is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mabxience-research-sl#company-drugs.

• What are the latest developments for mAbxience?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does mAbxience focus on?

  mAbxience focuses on Not applicable, Healthy Volunteers, advanced/metastatic non-squamous non-small cell lung cancer (NSCLC), Rheumatoid Arthritis based on our analysis of their pipeline programs and drug development activities.